CoChat

Esophageal carcinoma: Towards targeted therapies

Open access
Fatehi Hassanabad, Ali, Chehade, Rania, Breadner, Daniel, Raphael, Jacques · 2020 · Cellular Oncology

The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Patients with esophageal cancer are confronted with high mortality rates. Whether it is esophageal squamous cell carcinoma (ESCC) or esophageal adenocarcinoma (EAC), patients usually present at advanced stages, with treatment options traditionally involving chemotherapy in metastatic settings. With the comprehensive genomic characterization of esophageal cancers, targeted therapies are gaining interest and agents such as ramucirumab, trastuzumab and pembrolizumab are already being used for the treatment of EAC. CONCLUSIONS: Pembrolizumab has recently been FDA-approved for PD-L1 positive, locally advanced or metastatic ESCC. Despite comprehensive molecular characterization, however, available targed therapies for ESCC are still lagging behind. Herein, we discuss current trends towards more targeted therapies in esophageal cancers, taking into consideration unique features of ESCCs and EACs. Patients progressing on standard therapies should be subjected to genomic profiling and considered for clinical trials aimed at testing targeted therapies. Future targeted therapies may include CDK4/6 inhibitors, PARP inhibitors and inhibitors targeting the NRF2 and Wnt signaling pathways. Ultimately, optimized biomarker assays and next generation sequencing platforms may allow for the identification of subcategories of ESCC and EAC patients that will benefit from selective targeted therapies and/or combinations thereof.

Overview

Integrity signals

Registry

Crossref · 10.1007/s13402-019-00488-2

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 83 references

Research works printed but not linked: 1

  1. Available from: https://www.ascopost.com/issues/april-10-2019-supplement-conference-highlights-gugi-2019/keynote-181-in-esophageal-cancer/. Accessed 19 October 2019

Cited by

Items 101–159 of 159

Metadata

Authors
Fatehi Hassanabad, A., Chehade, R., Breadner, D., & Raphael, J.
Affiliations
Western University (CA)
Venue
Cellular Oncology
Published
2019-12-17
Volume
43
Issue
2
Pages
195-209
ISSN
  • 1570-5870 (ISSN-L)
  • 2211-3428
  • 2211-3436
OpenAlex
W2994654968
Cited by
158
References
83
Citations by year
2026: 5 · 2025: 17 · 2024: 29 · 2023: 20 · 2022: 44 · 2021: 29 · 2020: 14
FWCI
4.54
Type
journal article
Language
en
Open access
Licence
Locations
  • Cellular Oncology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Esophageal Cancer Research and Treatment
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
esophageal squamous cell carcinoma, esophageal adenocarcinoma, targeted therapy, pembrolizumab, PD-L1, ramucirumab, trastuzumab, CDK4/6 inhibitors, PARP inhibitors, Nrf2 signaling, Wnt signaling, genomic profiling, biomarkers, metastatic esophageal cancer
MeSH terms
Adenocarcinoma, Carcinoma, Squamous Cell, Enzyme Inhibitors, Esophageal Neoplasms, Humans, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Molecular Targeted Therapy, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.